This a competing renewal application (Type 2) for a Center to prepare adult stem/progenitor cells from the bone marrow of human volunteers and rodents, define the quality of the cells, and then distribute them to multiple investigators. The adult stem/progenitor cells we prepare were originally referred to as fibroblastic colony-forming-units, then as marrow stromal cells in the hematological literature, subsequently as mesenchymal stem cells, and most recently as multipotent mesenchymal stromal cells or MSCs. Since the last competitive renewal, we made 627 shipments of 1,075 vials of frozen MSCs to over 280 scientists of whom 157 are funded by 18 NIH Institutes. We have received over 140 Letters of Support.
The Aims are: (1) To continue to produce standardized preparations of human MSCs (hMSCs) for distribution to other investigators. We will transduce some of the hMSCs with lentiviruses to express genes useful in tracking the cells both in culture and in vivo: with cytoplasmic green fluorescent protein (GFP), mitochondrial red fluorescent protein (MitoRed) and luciferase. (2) To continue to provide similar preparations of mouse MSCs (mMSCs) for distribution to other investigators. (3) To continue to provide similarly characterized preparations of rat MSCs (rMSCs) for distribution to other investigators. We will continue to prepare rMSCs from other rat strains and from transgenic rats ubiquitously expressing GFP as a marker for experiments in culture and in vivo. (4) In exploratory research (up to 10% of allocated funds), we will compare the genes expressed by different standard preparations of hMSCs and hMSCs pre-activated in culture by cytokines using microarrays, qRT-PCR and ELISAa for secreted factors. The data will be analyzed to identify the preparations with the highest levels of expression of anti-inflammatory and immune regulatory genes. The results will be provided to recipients of the hMSCs and scientists will be encouraged to compare preparations that the data suggest may vary in efficacy in the systems they are testing. We will provide assistance from a collaborating expert in bioinformatics in evaluating the data.

Public Health Relevance

There is now great interest in mesenchymal stem/progenitor cells (MSCs) with over 17,000 citations in the common search engine (PubMed) and over 150 registered clinical trials (www.clinicaltrials.gov). However, there are differences in the protocols to prepare the cells and the final quality of the cells. This Centr provides investigators with thoroughly characterized MSCs that they can use as a reference standard for their experiments

Agency
National Institute of Health (NIH)
Institute
Office of The Director, National Institutes of Health (OD)
Type
Animal (Mammalian and Nonmammalian) Model, and Animal and Biological Material Resource Grants (P40)
Project #
2P40OD011050-11
Application #
8472687
Study Section
Special Emphasis Panel (ZTR1-CM-6 (01))
Program Officer
Mirochnitchenko, Oleg
Project Start
2013-06-15
Project End
2018-05-31
Budget Start
2013-06-15
Budget End
2014-05-31
Support Year
11
Fiscal Year
2013
Total Cost
$983,795
Indirect Cost
$309,963
Name
Texas A&M University
Department
Type
Schools of Medicine
DUNS #
835607441
City
College Station
State
TX
Country
United States
Zip Code
77845
Bazhanov, Nikolay; Ylostalo, Joni H; Bartosh, Thomas J et al. (2016) Intraperitoneally infused human mesenchymal stem cells form aggregates with mouse immune cells and attach to peritoneal organs. Stem Cell Res Ther 7:27
Prockop, Darwin J (2016) Inflammation, fibrosis, and modulation of the process by mesenchymal stem/stromal cells. Matrix Biol 51:7-13
Mittal, Manish; Tiruppathi, Chinnaswamy; Nepal, Saroj et al. (2016) TNFα-stimulated gene-6 (TSG6) activates macrophage phenotype transition to prevent inflammatory lung injury. Proc Natl Acad Sci U S A 113:E8151-E8158
Xie, Jie; Broxmeyer, Hal E; Feng, Dongni et al. (2015) Human adipose-derived stem cells ameliorate cigarette smoke-induced murine myelosuppression via secretion of TSG-6. Stem Cells 33:468-78
Beltran, Stacy R; Svoboda, Kathy K H; Kerns, David G et al. (2015) Anti-inflammatory protein tumor necrosis factor-*-stimulated protein 6 (TSG-6) promotes early gingival wound healing: an in vivo study. J Periodontol 86:62-71
Zhao, Qingguo; Gregory, Carl A; Lee, Ryang Hwa et al. (2015) MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs. Proc Natl Acad Sci U S A 112:530-5
Hoffman, Michael D; Benoit, Danielle S W (2015) Emulating native periosteum cell population and subsequent paracrine factor production to promote tissue engineered periosteum-mediated allograft healing. Biomaterials 52:426-40
Jung, Youngmee; Ji, HaYeun; Chen, Zaozao et al. (2015) Scaffold-free, Human Mesenchymal Stem Cell-Based Tissue Engineered Blood Vessels. Sci Rep 5:15116
Agarwal, Rachit; González-García, Cristina; Torstrick, Brennan et al. (2015) Simple coating with fibronectin fragment enhances stainless steel screw osseointegration in healthy and osteoporotic rats. Biomaterials 63:137-45
Foskett, Andrea M; Bazhanov, Nikolay; Ti, Xinyu et al. (2014) Phase-directed therapy: TSG-6 targeted to early inflammation improves bleomycin-injured lungs. Am J Physiol Lung Cell Mol Physiol 306:L120-31

Showing the most recent 10 out of 32 publications